Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
University of Parma · Amsterdam UMC Location Vrije Universiteit Amsterdam · +2 more institutions
Abstract
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals. On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous,…
Citation impact
- FWCI
- 86.06
- Percentile
- 100%
- References
- 110
Authors
6- ALAlessandro LeonettiCorresponding
University of Parma, Amsterdam UMC Location Vrije Universiteit Amsterdam
- SSSugandhi Sharma
Amsterdam UMC Location Vrije Universiteit Amsterdam
- RMRoberta Minari
University of Parma
- PPPaola Perego
Fondazione IRCCS Istituto Nazionale dei Tumori
- EGElisa Giovannetti
Fondazione Pisa, Amsterdam UMC Location Vrije Universiteit Amsterdam
Topics & keywords
- Osimertinib
- T790M
- Lung cancer
- Epidermal growth factor receptor
- Cancer research
- Tyrosine kinase
- Biology
- Medicine
- Good health and well-being